Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Latest filing published 20 Nov 2023 for RESMED INC, €188k. Read the official filing
Filing timeline
BuySaleRobert Andrew Douglas
Insider track record
Disclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Robert Andrew Douglas: trading record in brief
Robert Andrew Douglas, listed as chief executive, appears in our data through filings on ResMed Inc shares, published by SEC (Form 4). We count 34 filings; the first trade dates from 4 January 2016 and the latest from 20 November 2023.
Sales make up the whole of the open-market record (10 sales, €3.4M). The totals exclude 2 filings filed without an amount. The rest of the record consists of 8 share grants and 14 option exercises. 2023 to date brings no purchases and 7 sales.
The record was last updated on 20 November 2023 with a share grant (€188k) in ResMed Inc. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Robert Andrew Douglas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations34 total
1,375.219 shares@ US$148.940.6% of flowResMed Common StockSEC:0001127602-23-028064:0
944.542 shares@ US$143.600.4% of flowResMed Common StockSEC:0001127602-23-027465:0
1,500 shares@ US$181.010.8% of flowResMed Common StockSEC:0001127602-23-022703:0
1,500 shares@ US$222.220.9% of flowResMed Common StockSEC:0001127602-23-020952:0
1,500 shares@ US$216.270.9% of flowResMed Common StockSEC:0001127602-23-018944:0
1,500 shares@ US$232.851.0% of flowResMed Common StockSEC:0001127602-23-015793:0
1,500 shares@ US$224.650.9% of flowResMed Common StockSEC:0001127602-23-013175:0
1,919 shares0ResMed Common StockSEC:0001127602-23-010444:0
1,500 shares@ US$213.500.9% of flowResMed Common StockSEC:0001127602-23-005682:0
1,500 shares@ US$220.430.9% of flowResMed Common StockSEC:0001127602-23-001652:0
32,795 shares0ResMed Common StockSEC:0001127602-22-026361:0
1,144 shares@ US$58.240.2% of flowResMed Common StockSEC:0001127602-22-025832:0
945 shares@ US$225.180.6% of flowResMed Common StockSEC:0001127602-22-025659:0
1,145 shares@ US$58.240.2% of flowResMed Common StockSEC:0001127602-22-023989:0
1,145 shares@ US$58.240.2% of flowResMed Common StockSEC:0001127602-22-022565:0
4,328 shares0ResMed Common StockSEC:0001127602-22-021422:0
8,000 shares@ US$58.240.0011% mcap1.4% of flowResMed Common StockSEC:0001127602-22-012108:0
8,000 shares@ US$58.240.0011% mcap1.4% of flowResMed Common StockSEC:0001127602-22-009455:0
8,000 shares@ US$58.242.2% of flowResMed Common StockSEC:0001127602-22-005282:0
8,000 shares@ US$58.242.2% of flowResMed Common StockSEC:0001127602-22-001741:0
8,000 shares@ US$58.242.2% of flowResMed Common StockSEC:0001127602-21-031222:0
791 shares0ResMed Common StockSEC:0001127602-21-029820:0
45,811 shares@ US$254.8155.1% of flowResMed Common StockSEC:0001127602-21-029557:0
945 shares@ US$259.471.1% of flowResMed Common StockSEC:0001127602-21-029234:0
8,000 shares@ US$58.242.2% of flowResMed Common StockSEC:0001127602-21-027245:0
25 of 34 declarations
